Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
2.150
-0.170 (-7.33%)
At close: Mar 17, 2026, 4:00 PM EDT
2.130
-0.020 (-0.93%)
After-hours: Mar 17, 2026, 7:27 PM EDT
Equillium Revenue
Equillium had revenue of $4.39M in the twelve months ending September 30, 2025, down -90.43% year-over-year. In the year 2024, Equillium had annual revenue of $41.10M with 13.89% growth.
Revenue (ttm)
$4.39M
Revenue Growth
-90.43%
P/S Ratio
29.81
Revenue / Employee
$125,486
Employees
35
Market Cap
130.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.10M | 5.01M | 13.89% |
| Dec 31, 2023 | 36.08M | 20.33M | 128.97% |
| Dec 31, 2022 | 15.76M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 70.39M |
| Sangamo Therapeutics | 32.88M |
| Innate Pharma | 14.84M |
| Fate Therapeutics | 6.65M |
| Ovid Therapeutics | 6.61M |
| Oramed Pharmaceuticals | 2.00M |
| Rani Therapeutics Holdings | 1.20M |
| Cardiff Oncology | 593.00K |
EQ News
- 4 days ago - Equillium Announces $35 Million Financing with RA Capital Management - GlobeNewsWire
- 20 days ago - Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC - Seeking Alpha
- 20 days ago - Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Equillium to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 4 months ago - Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript - Seeking Alpha
- 5 months ago - Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025 - GlobeNewsWire